secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001193125-26-153923
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus completes enrollment in CANYON-1 Phase 1b trial of CRB-913 for obesity; on track for summer 2026 data
--------------------------------------------------------------------------------

- Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.
- Trial is a 16-week, placebo-controlled, dose-ranging study (n=240) with 20, 40, and 60 mg QD cohorts; completion expected summer 2026.
- Phase 1a data showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort, with no vomiting, constipation, or nausea reported.
- Neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) were negative across all cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/0001193125-26-153923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/crbp-20260414.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-153923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer